🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥NeoPancOne🇨🇦 ➡️mFFX in resectable PDAC ➡️exploring GATA6&subtypes ➡️mEFS &OS 16.3 &34.2mths ➡️1yr EFS 90% in GATA6 hi vs 50% lo ➡️1yr OS classical 95% vs.57% basal-like ⭐️Time to subtype upfront in all PDAC recognising plasticity OncoAlert #ASCO25 Ontario Institute for Cancer Research (OICR) Princess Margaret Cancer Centre

It’s official! Dr. Eric Small assumes his role as @asco 2025-26 president and introduces his theme. #asco25 ASCOPres

Dr. Patrick Forde presents final OS results from CheckMate 816 at #ASCO25. Adding nivolumab to 3 cycles of neoadjuvant chemotherapy for resectable NSCLC improves OS with HR 0.72 and 5y OS rate 65% vs 55%. Effect greater in PDL1+ (HR 0.51) than PDL1 negative (HR 0.89).

Dr. Jamie Chaft with NEOADAURA at #ASCO25. Neoadjuvant osimertinib alone or with chemo vs neoadjuvant chemo in NSCLC. MPR only 2% with chemo, vs 25% with osi, 26% with osi/chemo. pCR 9% osi, 4% osi/chemo. EFS better for pts who MPR - curious how adjuvant osi contributed to EFS.

Multiple studies looking at neoadjuvant regimens for HER2+ early BC. Looks like THP would suffice for most stage 1 and 2, and Cb not needed. Interesting question as to whether 6 cycles / 18 weeks is > than 4 cycles / 12 weeks. ASCO #ASCO25 OncoAlert

☢️ Futility of atezolizumab + SBRT in early stage NSCLC. #ASCO25 #lcsm

Not suprising, this is as we thought, but amazing that it was formally tested and done. Sorry..scalp cooling does not work for T-DXd and I would extrapolate to other #ADCs with long half lives. #hairloss #bcsm #ASCO25 #scalpcooling

~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! nejm.org/doi/full/10.10… #LCSM 1/

Excellent summary slides for current evidence for pancreatic cancer treatment . Useful for quick reference. @asco #asco25 taken from talk by Dr Brian Wolpin 👍OncoAlert ONCO BRUNO

Devastating disease and we need to do better. Greatest summary on where we are today in Pancreatic Cancer! #ASCO25

Congratulations to the top posters! 🏆🏆🏆 Aakash Desai, MD, MPH, FASCO Erman Akkus Oncology Brothers Paolo Tarantino Dr. Nina Niu Sanford Dr Amol Akhade Harold J. Burstein, MD, PhD, FASCO OncoAlert Arndt Vogel Toni Choueiri, MD

Yakup Ergün Raffaele Giusti I'd like to add that for oncologists in low- and middle-income countries (LMICs), social media is not a threat—it’s a lifeline. Before platforms like X (formerly Twitter), global oncology discourse was largely one-sided: knowledge flowed from elite

Dr Amol Akhade Yakup Ergün Raffaele Giusti Well-said. Oncologists in LMICs, that’s us 🙋‍♀️😂. Thank you to you and all other countless KOLs here in X, conference updates reach us at almost the exact moment they unfold elsewhere - in comprehensive summaries at that. From our patients and us - thank you 🙏🏽🙂

Dr Amol Akhade Yakup Ergün Raffaele Giusti How wonderful to read these interactions, I work in the Peruvian jungle #puertomaldonado where we are starting a project for access to oncology, it is very inspiring to be connected globally through a digital platform.

Useful slide to explain clinical outcomes for pts with 1st line, 2nd line and Beyond For HR+ /Her2 -ve MBC . Money 💰 slide by Komal Jhaveri @asco #asco25 OncoAlert Oncology Brothers

Thank you for sharing your insights, Erman Akkus! "Thanks to X, during ASCO and other major meetings, real-time trial updates, expert analyses, and post-session debates are accessible to everyone" -- Dr Amol Akhade We deeply value your contributions and everyone who shared

This is how it should be . Rare disease treatment needs priority . At the same time , I am sure stage 4 pancreatic cancer and metastatic breast cancer ( or any similar subset) will not be considered as rare disease. With great power comes great responsibility

Another money 💰 slide from #asco25 ASCO . Treatment algorithm for HR +/ HER 2 -ve mBC OncoAlert Kate Sears